Table 4 Clinico-pathological data of patients with unavailable chemotherapy-related toxicity data
From: D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy
Patient data (n = 40) | |
|---|---|
Clinical data | |
Median age in years (range) | 52.5 (23 to 85) |
Sex (M:F) | 28:12 (70%:30%) |
Tumor location (endoscopic) | |
Gastro-esophageal region | 11 |
Pyloric-antrum | 22 |
Body | 3 |
Fundus | 3 |
Whole stomach, linitis plastica-type | 1 |
Surgeries | |
Total gastrectomy | 10 |
Proximal gastrectomy | 7 |
Subtotal gastrectomy | 13 |
Inoperable/palliative surgeries | 10 |
Median blood loss in ml (range) | 500 (100 to 1000) |
Median units of blood transfused (range) | 0 (0 to 1) |
Morbidity ratea | 16.6% (5) |
Mortality rate | 0% (0) |
Median duration of hospital stay in days (range) | 9 (3 to 35) |
Histopathological data of patients who underwent radical resections | Patient data (n = 30) |
Final pathology | |
Well-differentiated adenocarcinoma | 1 |
Moderately-differentiated adenocarcinoma | 8 |
Poorly differentiated adenocarcinoma | 11 |
Signet ring cell adenocarcinoma | 7 |
Microscopic foci of adenocarcinoma | 1 |
No residual tumor | 2 |
T-stage | |
T1 | 2 |
T2 | 9 |
T3 | 12 |
T4 | 5 |
Perineural invasion present | 6 (20%) |
Lymphovascular invasion present | 13 (43%) |
Median number of lymph nodes harvested (range) | 15 (1 to 36) |
Median number of positive nodes (range) | 1 (0 to 14) |
Positive microscopic resection margin | 4 (13%) |